戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 extracellular matrix (via laminin, agrin, or perlecan).
2 s collagenic tail (ColQ) to the proteoglycan perlecan.
3 an sulfate proteoglycans (HSPGs), especially perlecan.
4 ot to basement membranes containing the HSPG perlecan.
5 4(V)-NTD-binding proteins are glypican-1 and perlecan.
6 nd phosphorylation of FAK and Akt of SMCs on perlecan.
7 lar matrices, with a distribution similar to perlecan.
8 or significantly reduced levels of wild-type perlecan.
9 ted in reduced amounts of nearly full-length perlecan.
10 teins that interact with the protein core of perlecan.
11 lanogaster homolog of the vertebrate protein Perlecan.
12  membrane including laminin-5, entactin, and perlecan.
13  an antisense vector targeting domain III of perlecan.
14  showed a decrease in the HSPG core protein, perlecan.
15 r roles as cell surface attachment sites for perlecan.
16 ies secreted into the media were decorin and perlecan.
17 ributed to the heparan sulfate GAG chains of perlecan.
18 ts with the glycosaminoglycan side chains of perlecan.
19 ellular matrix heparan sulfate proteoglycan, perlecan.
20  a skeletal disease resulting from decreased perlecan.
21                                              Perlecan (10 microg/ml) evoked unreportedly high, in vit
22 ersican (3.2-fold), biglycan (2.0-fold), and perlecan (2.0-fold), whereas decorin mRNA levels decreas
23 ranscripts, which encode the core protein of perlecan, a basement membrane proteoglycan.
24 secreted heparan sulfate proteoglycan (HSPG) perlecan, a component of the extracellular matrix.
25                                              Perlecan, a heparan sulfate proteoglycan of basement mem
26                                              Perlecan, a heparan sulfate proteoglycan, has been sugge
27                                              Perlecan, a HSPG normally confined to the mesangium in m
28                                              Perlecan, a large heparan sulfate proteoglycan, is a com
29                                              Perlecan, a large, multi-domain, heparan sulfate proteog
30                               We now studied perlecan, a major cell surface HSPG genetically distinct
31   In an in vivo search of novel partners for perlecan, a major heparan sulfate proteoglycan of baseme
32 his study was to discover novel partners for perlecan, a major heparan sulfate proteoglycan of baseme
33                            Here we show that perlecan, a multifunctional heparan sulfate proteoglycan
34                                              Perlecan, a ubiquitous basement membrane heparan sulfate
35                                              Perlecan, a ubiquitous heparan sulfate proteoglycan, pos
36                                              Perlecan, a widespread heparan sulfate proteoglycan, fun
37 ondrocytes had intracellular accumulation of perlecan, an extracellular matrix protein, but not of ty
38 use et al. demonstrate that dystroglycan and perlecan, an extracellular matrix receptor and its ligan
39  be considered a novel biological ligand for perlecan, an interaction that could influence cancer gro
40                  These results indicate that perlecan and aggrecan would be the principal candidate p
41 of 200 kDa and larger and were identified as perlecan and aggrecan.
42  study shows that collagen XVIII is, next to perlecan and agrin, the third basal lamina heparan sulfa
43 oimmunoprecipitated with an antibody against perlecan and bound in solution to recombinant domain III
44                                              Perlecan and ECM1 were also co-expressed by a variety of
45                      Here, we show that both perlecan and endorepellin bind directly and with high af
46 is, levels of the basement membrane proteins perlecan and fibronectin were severalfold higher than in
47 chanical strain stimulated the production of perlecan and heparan sulfate glycosaminoglycans by endot
48 n surface glia, AdamTS-A acts in parallel to perlecan and in opposition to viking/collagen IV and bet
49 xperiments to investigate the involvement of perlecan and its C-terminal domain V/endorepellin in zeb
50 her basement membrane components) as well as perlecan and laminin isoforms.
51                    Collagen IV, pan-laminin, perlecan and laminin-alpha5 in the islet BM were signifi
52     Finally, we examined cooperation between perlecan and low density lipoprotein receptors and found
53  that trol encodes the Drosophila homolog of Perlecan and regulates neuroblast division by modulating
54 nized mesenchyme, with reduced expression of perlecan and semaphorin 3C, and exhibited disorganized F
55 ns between Trol and Hh and between mammalian Perlecan and Shh that are not competed with heparin sulf
56 cells revealed that the HSPG increase was in perlecan and that apoE also stimulated perlecan mRNA exp
57 te-decorated extracellular biomolecule named perlecan and the research relating to its potential as a
58 pericellular coats of HA selectively reduced perlecan and versican turnover, whereas other proteoglyc
59 propose delivery and application schemes for perlecan and/or its domains in bone-regenerative procedu
60  extracellular matrix glycoproteins laminin, perlecan, and agrin mediate the binding to heparin and t
61 aminin-1, nidogen-1, collagens IV and XVIII, perlecan, and agrin.
62 onnexin 43, type IV collagen, laminin-5, and perlecan, and apoptosis was determined by TUNEL or cell-
63 e-2 and increased the synthesis of versican, perlecan, and decorin/biglycan.
64                          Versican, biglycan, perlecan, and hyaluronan were present with varying indiv
65 x (ECM) molecules such as Laminin, agrin and perlecan, and plays a role in linking the ECM to the act
66 on between the heparan sulfate proteoglycan, perlecan, and PTEN in the regulation of vascular smooth
67 r, including uvomorulin, integrin alpha8 and perlecan, and suggest that WTI may activate the IGF-II g
68 f syndecan-1, syndecan-4, glypican, decorin, perlecan, and versican.
69 bation with either anti-endorepellin or anti-perlecan antibodies.
70                                      An anti-perlecan antibody completely abrogated the antiprolifera
71 nstrate that cell-surface syndecan-1 and ECM perlecan are degradative targets of HPSE-1, and syndecan
72                                  Nidogen and perlecan are large multifunctional basement membrane (BM
73 inin 10, collagen IV, and nidogen-2 (but not perlecan) are considerably lower (<60%) than the average
74 cellular matrix, such as laminin, agrin, and perlecan, are not abundant in brain except in the periva
75          We identify the dystroglycan-ligand perlecan as a novel nodal component and show that dystro
76 kbone and GAG sulfate content, and implicate perlecan as an important macromolecule that is likely in
77 he yeast two-hybrid system and domain III of perlecan as bait, we screened approximately 0.5 10(6) cD
78 s required for the selective accumulation of perlecan at nodes.
79 us controls that produce abundant amounts of perlecan at this developmental time point.
80                                              Perlecan augments the reduction in phospho-focal adhesio
81 ing perlecan to mutant motor neurons rescues perlecan axon guidance defects.
82 1 and serum induced substantial increases in perlecan bearing chondroitin sulfate and/or heparan sulf
83                                The levels of perlecan bearing chondroitin sulfate chains were elevate
84 r extended periods in culture, the amount of perlecan bearing heparan sulfate chains was unaffected b
85  proteins studied, the effects are unique to perlecan, because plating of SMCs on several other basem
86 cell-surface and matrix proteoglycans (e.g., perlecan, biglycan, and syndecans 1 and 3) and mitogenes
87                     Because both decorin and perlecan bind growth factors and are proposed to modulat
88 dentified, activity of nidogen overlaps with perlecan binding and accounts for the unusually high deg
89                                              Perlecan binds the clustering molecule gliomedin and enh
90     Endorepellin (the C-terminal domain V of perlecan) binds the alpha2beta1 integrin on endothelial
91                             Cells expressing perlecan but no other proteoglycans bound, internalized,
92 iogenic heparan sulfate proteoglycan (HSPG), perlecan, but not other HSPGs, is dramatically down-regu
93 ulfate and to BM components like laminin and perlecan, but the functional role of these interactions
94 ts stained poorly with antibody specific for perlecan, but there was staining of intracellular inclus
95                                          The perlecan c-terminal fragment LG3 is generated at increas
96 x composed of large glycoproteins, including perlecan, collagens, and laminins.
97 f the specific heparan sulfate proteoglycan, perlecan, colocalized to islet amyloid deposits, similar
98                  Therefore, the dystroglycan-perlecan complex serves as a cell surface acceptor for A
99                                              Perlecan contained 25% heparan sulfate and 75% chondroit
100 t other products (e.g., apolipoprotein E and perlecan) contained within islet amyloid may be necessar
101 y connected in a spot-welding-like manner by perlecan-containing aggregates.
102                             After removal of perlecan-containing suprastructures or after enzyme dige
103 train also increased versican, biglycan, and perlecan core proteins, with a concomitant decrease in d
104 helial cells prevented occlusive thrombosis, perlecan-deficient cells were completely ineffective.
105 tly reconstitutes FGF7 mitogenic activity in perlecan-deficient cells.
106 y reconstituted the activity of FGF-7 in the perlecan-deficient cells.
107                                              Perlecan-deficient mice did not display demyelination ev
108 ization of myelinating Schwann cells because perlecan-deficient mice had shorter internodes, more num
109 ased PTEN activity was detected in aortas of perlecan-deficient mouse embryos, consistent with SMC hy
110 rotein receptor-related protein did not slow perlecan-dependent internalization.
111 ased PTEN activity associated with increased perlecan deposition and decreased SMC replication rates.
112 D fibroblasts, and augmented fibronectin and perlecan deposition in all three groups.
113 cult to dissect in placental animals because perlecan disruption is embryonic lethal.
114  drying and loaded with plasmid DNA encoding perlecan domain I and VEGF189 and analyzed in vivo for t
115                     The plasmid DNA encoding perlecan domain I and VEGF189 loaded scaffolds promoted
116  containing plasmid DNA encoding VEGF189 and perlecan domain I have the potential to induce angiogene
117                                              Perlecan Domain V (DV) promotes brain angiogenesis by in
118 mployed the yeast two-hybrid system and used perlecan domain V as bait to screen a human keratinocyte
119          The interaction of progranulin with perlecan domain V involved the first two laminin- and ep
120                   These results suggest that perlecan domain V represents a promising approach for st
121 r-like modules flanking the LG2 subdomain of perlecan domain V.
122 rn blot analysis revealed elevated levels of perlecan domain V.
123  likely the heparan sulfate chain present on perlecan domain V.
124 y occurring extracellular matrix fragment of perlecan, domain V, which we found had neuroprotective p
125 l insight into the role of the ECM component Perlecan during Drosophila hematopoiesis.
126                                    Exogenous perlecan effectively reconstituted the activity of FGF-7
127  to perlecan protein core and that exogenous perlecan efficiently reconstitutes FGF7 mitogenic activi
128 fibronectin, serum-stimulated SMCs plated on perlecan exhibited increased PTEN activity, decreased FA
129 helial cells, blocked the down-regulation of perlecan expression and antiproliferative activity of cl
130                           Down-regulation of perlecan expression by cleaved and latent antithrombins
131                    In this report we blocked perlecan expression by using either constitutive CMV-dri
132                     Mechanical regulation of perlecan expression in endothelial cells was governed by
133 growth factor-beta 1, a potent stimulator of perlecan expression in endothelial cells, blocked the do
134                            The importance of perlecan expression levels in mediating the antiprolifer
135                           Down-regulation of perlecan expression suppresses the invasive behavior of
136 ecause other growth modulators also regulate perlecan expression, this may be a key pathway in the re
137 ir effects is through the down-regulation of perlecan expression.
138 n correlated with their ability to stimulate perlecan expression.
139 DGF-BB, whereas both PDGF isoforms decreased perlecan expression.
140 illin-1) or in combination with fibronectin (perlecan, fibulin-2), in the absence of feeder cells.
141 lular matrix proteins, including nidogen and perlecan (Figure 1, bottom).
142           Altogether, our data shed light on perlecan function by revealing critical roles in Schwann
143                                              Perlecan functions as a ligand reservoir for various gro
144                     These data indicate that perlecan functions as an endogenously produced inhibitor
145                             Mutations in the perlecan gene (HSPG2) cause two classes of skeletal diso
146                             Mice lacking the perlecan gene (Hspg2) have a severe chondrodysplasia wit
147 we investigated the activity of IFN-gamma on perlecan gene expression and cell growth in colon carcin
148 was markedly attenuated upon obliteration of perlecan gene expression and these effects correlated wi
149 broblast growth factor (bFGF) signaling, and perlecan gene expression in bFGF-stimulated human umbili
150 at IFN-gamma rapidly and efficiently blocked perlecan gene expression with concurrent growth suppress
151        The transcriptional repression of the perlecan gene required intact Stat1 protein, and these e
152 his increased LG3 is the result of increased perlecan generation and cellular release, increased prot
153 anulin, the subdomains interacting most with perlecan harbored granulins F and B.
154 rils and glycosaminoglycans, suggesting that perlecan has an important role in matrix structure.
155                  These findings suggest that perlecan has an important role in neuromuscular function
156       Endorepellin, the C-terminal module of perlecan, has angiostatic activity.
157 ad a higher affinity for endothelial-derived perlecan heparan sulfate chains than serglycin GAG chain
158 lin to perlecan was similarly observed using perlecan heparan sulfate glycosaminoglycans (GAGs), and
159 d the FGF10-FGFR2b complex bound to purified perlecan HS and could be released by heparanase.
160  results show heparanase releases FGF10 from perlecan HS in the basement membrane, increasing MAPK si
161 degrades HS chains of purified syndecan-1 or perlecan HS.
162 in DM appears to be due to decreased hepatic perlecan HSPG.
163          We have disrupted the gene encoding perlecan (Hspg2) in mice.
164 s (GPCs), the basement membrane proteoglycan perlecan (HSPG2), and agrin.
165 lar to the fibronectin binding Ig domains of Perlecan/HSPG2.
166                                              Perlecan IG3 belongs to the I-set of the IG superfamily
167 t 2.0 A resolution of the mouse nidogen-1 G2-perlecan IG3 complex.
168 the third immunoglobulin (IG)-like domain in perlecan, IG3.
169 soluble FGF-7 specifically bound immobilized perlecan in a heparan sulfate-independent manner.
170 uding the genes for collagen 2, aggrecan and perlecan in both notochord cells and surrounding chondro
171 ur findings demonstrate the critical role of perlecan in cartilage development.
172 ant site and that cleave LG3 from endogenous perlecan in cultured mouse and human cells.
173 e of the heparan sulfate proteoglycan (HSPG) perlecan in islet amyloid deposits, suggesting a role fo
174 ohistochemistry revealed reduced staining of perlecan in kidney from apoE-null mice.
175       The previously established key role of perlecan in mediating bFGF stimulation of endothelial ce
176 zed sarcomeres, suggesting an involvement of perlecan in myopathies.
177 that SMC adhesion to basement membranes, and perlecan in particular, up-regulate the expression of fo
178 e SJS mutations result in different forms of perlecan in reduced levels that are secreted to the extr
179 nd degradation of fibrin(ogen), nidogen, and perlecan in the adventitia of descending aortas.
180 is not required for the deposition of UNC-52/perlecan in the basal lamina, nor for the initiation of
181 ranase, an endoglycosidase, colocalized with perlecan in the basement membrane and in epithelial clef
182 robe for HS in SMGs, and it colocalized with perlecan in the basement membrane and partly colocalized
183                       We revealed a role for perlecan in the longitudinal elongation and organization
184 alyses revealed colocalization of FGF-BP and perlecan in the pericellular stroma of various squamous
185 model of SJS to determine whether a role for perlecan in these functions could account for PNH when p
186  mutations that resulted in various forms of perlecan in three unrelated patients with SJS.
187 ession of constitutively active Akt reversed perlecan-induced SMC growth arrest while morpholino anti
188  growth and increased PTEN activity mediates perlecan-induced suppression of SMC proliferation.
189  reduction in cell spreading, we report that perlecan-induced up-regulation of FRNK is independent of
190 l domain of the heparan sulfate proteoglycan perlecan, inhibits angiogenesis by simultaneously bindin
191  the vascular basement membrane proteoglycan perlecan, inhibits angiogenesis via the alpha2beta1-inte
192 l domain of the heparan sulfate proteoglycan perlecan, inhibits several aspects of angiogenesis.
193 inin-5, type IV collagen, type VII collagen, perlecan, integrin alpha6, and epithelial cell different
194                            Thus, progranulin/perlecan interaction could contribute to a fine regulati
195 lts uncover incorporation of Collagen IV and Perlecan into BMs as a major determinant of organ shape
196 e and process the extracellular proteoglycan perlecan into fragments containing the endorepellin C-te
197                                              Perlecan is a large heparan sulfate (HS) proteoglycan pr
198                                              Perlecan is a multifaceted heparan sulfate proteoglycan
199                                        Thus, perlecan is a potent inducer of tumor growth and angioge
200                  Our previous studies showed perlecan is a potent inhibitor of serum-stimulated SMC g
201                   Thus, these data show that perlecan is a potent inhibitor of SMC proliferation and
202                     Up-regulation of FRNK by perlecan is actively and continuously regulated.
203                                              Perlecan is discussed as a potential biological adjunct
204                 These findings indicate that perlecan is essential for the integrity of somitic muscl
205  neurons during OGD and de novo synthesis of perlecan is increased during reperfusion, even 24 h afte
206 n these functions could account for PNH when perlecan is lacking.
207 d, whereas the corresponding binding site on perlecan is more variable.
208                                              Perlecan is present in a variety of basement membranes a
209                                      Because perlecan is present in both endothelial and smooth muscl
210                                   Therefore, perlecan is required for Sema-1a-PlexA-mediated repulsiv
211                                              Perlecan is the major HSPG of mesangial matrix and suben
212       Endorepellin, the C-terminal domain of perlecan, is a powerful angiogenesis inhibitor.
213       Endorepellin, the C-terminal domain of perlecan, is an angiostatic molecule that acts as a pote
214                    Conversely, another HSPG, perlecan, is an important component of basement membrane
215                                              Perlecan knock-in mice were developed to model Schwartz-
216        The extracellular proteoglycan UNC-52/Perlecan linked the dense body to the hemidesmosome on t
217 glycan or in its extracellular matrix ligand Perlecan lose polarity under energetic stress.
218                We found that pre-synthesized perlecan may be exocytosed by neurons during OGD and de
219 nd to examine new interactions through which perlecan may influence cell behavior.
220 gamma-mediated transcriptional repression of perlecan may represent a novel antitumoral effect of thi
221                 Our results demonstrate that perlecan mediates internalization and lysosomal delivery
222 eritracheal distributions of collagen IV and Perlecan, misregulated ASP growth, and abrogated develop
223                                          The perlecan molecule, with its heparan sulfate glycosylatio
224                                          The perlecan morphants show a severe myopathy characterized
225                                       In the perlecan morphants, primary intersegmental vessel sprout
226 as in perlecan and that apoE also stimulated perlecan mRNA expression by >2-fold.
227 gation, the spatial and temporal patterns of perlecan mRNA expression in the mouse embryo during the
228  Sema-1a- and PlexA-null mutant embryos, and perlecan mutants genetically interact with PlexA and Sem
229               Motor axon guidance defects in perlecan mutants resemble those observed in Sema-1a- and
230       Endorepellin, the C-terminal module of perlecan, negatively regulates angiogenesis counter to i
231 t DM, type IV collagen alpha1-alpha6 chains, perlecan, nidogen-1, nidogen-2, and netrin-4 were found
232                      Starved Dystroglycan or Perlecan null cells activate AMPK normally, but do not a
233 s (EC) release LG3, a C-terminal fragment of perlecan of potential importance in vascular remodeling
234               The differential regulation by perlecan of these different aspects of vascular repair m
235 dies suggest that the enhancement effects of perlecan on amylin fibril formation are mediated primari
236 n, fibronectin, collagen type IV, agrin, and perlecan-on adhesion and TEER was assessed using an elec
237 partially rescued by microinjection of human perlecan or endorepellin.
238  LG3 from previous extracellularly deposited perlecan) or both.
239                              Collagen IV and perlecan originate predominantly from the lens epitheliu
240 ting that the heparan sulfate side chains of perlecan play a biologically important role in negativel
241                                   Similarly, perlecan plays an important role in chondrogenesis and s
242 embrane heparan sulfate proteoglycan (HSPG), perlecan (Pln), mRNA, and protein has been examined duri
243 mooth muscle cell (SMC) replication and that perlecan (PN), a basement membrane heparan sulfate prote
244                    In vitro experiments with perlecan-positive rat mesangial cells showed that FGF2-i
245 fragment of the heparan sulfate proteoglycan perlecan, possesses angiostatic activity via dual recept
246 l domain of the heparan sulfate proteoglycan perlecan, possesses angiostatic activity.
247         We discovered that the C terminus of perlecan potently inhibited four aspects of angiogenesis
248  LG domains of non-neural (muscle) agrin and perlecan promote AChR clustering in the presence of lami
249 t fibroblast growth factor-7 (FGF7) binds to perlecan protein core and that exogenous perlecan effici
250                                        Thus, perlecan protein core should be considered a novel biolo
251 ogical axis that links a soluble fragment of perlecan protein core to the major cell surface receptor
252 of FGF7 to various domains and subdomains of perlecan protein core.
253                                              Perlecan protein is found in both the CNS and the periph
254                        In the present study, perlecan purified from the Engelbreth-Holm-Swarm (EHS) t
255 mply that transcriptional changes leading to perlecan reduction may represent the disease mechanism f
256 space, and consistent with this, blockade of perlecan reversed the antiproliferative effect of apoE.
257                                              Perlecan's developmental functions are difficult to diss
258 th-Holm-Swarm (EHS) tumor was used to define perlecan's interactions with amylin (i.e., islet amyloid
259 alized to islet amyloid deposits, similar to perlecan's known involvement with other amyloid proteins
260 hanges in C1532Yneo mice, leading to reduced perlecan secretion and a skeletal disease phenotype char
261 s indicate that matrix proteoglycans such as perlecan serve as functional docking platforms for FGF2
262                                        Thus, Perlecan signaling through Dystroglycan may determine wh
263                                              Perlecan staining is weak in intermediate lesions but st
264                                              Perlecan supports SMC adhesion, although there is reduce
265 ced by highly invasive mouse melanoma cells, perlecan suppression caused substantial inhibition of tu
266 asia, however, was abrogated only in part by perlecan suppression.
267 ransfected cells produced significantly less perlecan than parent cells and showed a reduced ability
268         unc-52 encodes homologs of mammalian perlecan that are located extracellularly between muscle
269  patients with SJS either produced truncated perlecan that lacked domain V or significantly reduced l
270  which are also found in laminin, agrin, and perlecan, that are dystroglycan ligands.
271 ent membrane proteins, homologs of mammalian perlecan, that are important for body wall muscle assemb
272  PNH that is due to hypomorphic mutations of perlecan, the major proteoglycan of basement membranes.
273  PAT-4/ILK requires the ECM component UNC-52/perlecan, the transmembrane protein integrin, and the no
274                     We have previously shown perlecan to be selectively up-regulated in the glomeruli
275 It also requires conjugation of the agrin or perlecan to laminin together with laminin polymerization
276                                    Restoring perlecan to mutant motor neurons rescues perlecan axon g
277   There is deficiency of heparan sulfate and perlecan, together with accumulation of collagens, in th
278                            The C terminus of perlecan was active at nanomolar concentrations and bloc
279                          The core protein of perlecan was an exclusive component of this network wher
280          By several criteria, catabolism via perlecan was distinct from either coated pits or the syn
281 ith an antisense vector we demonstrated that perlecan was essential to the strain-mediated effects on
282  and electron microscopy methodology, intact perlecan was found to enhance amylin fibril formation in
283                        The binding of PF4 to perlecan was found to inhibit both FGF2 signaling and pl
284                          Internalization via perlecan was inhibited by genistein but unaffected by cy
285                                              Perlecan was linked to either chondroitin sulfate, hepar
286                     Biochemically, truncated perlecan was not secreted by the patient fibroblasts, bu
287 n of the matrix heparan sulfate proteoglycan perlecan was observed, along with massive accumulation o
288                         Growth inhibition by perlecan was rescued by overexpressing a constitutively
289               The binding of human amylin to perlecan was similarly observed using perlecan heparan s
290 finity to the heparan sulfate side chains of perlecan, we investigated the activity of IFN-gamma on p
291   The heparan sulfate chains on growth plate perlecan were considerably smaller than the chondroitin
292  (found in both layers of the duplex BM) and perlecan were lost entirely, with no restoration evident
293 otein E and the heparan sulfate proteoglycan perlecan, which are typically observed in other forms of
294 tering at the postsynaptic membrane requires perlecan, which binds both AChE and dystroglycan.
295 ting cells and second through recruitment of Perlecan, which counters constriction by Collagen IV.
296 me binds to the heparan-sulfate proteoglycan perlecan, which in turn binds to the dystroglycan comple
297  tissue stiffness and oppose the function of perlecan, which reduces tissue stiffness.
298 n, but not rat amylin, bound immobilized EHS perlecan with a single dissociation constant (Kd) = 2.75
299              By inhibiting the expression of perlecan with an antisense vector we demonstrated that p
300 1, produce the heparan sulfate proteoglycan, perlecan, with a molecular mass of 640 kDa as well as sm

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top